Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Menu
Seth Shipman, PhD
Seth Shipman, PhD
University of California San Francisco
San Francisco, CA
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Practice Question of the Week
October 12, 2026: Simplifying Antiretroviral Regimens in Virologically Suppressed Patients With Drug Resistance
You are caring for a patient who has a history of virologic failure with known nucleoside reverse transcriptase inhibitor (nRTI) and nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance. He has most recently been on darunavir (DRV)/cobicistat (cobi)/tenofovir alafenamide (TAF)/emtricitabine (FTC) + dolutegravir (DTG) with good tolerance, adherence, and viral suppression. Although this regimen is only 2 pills per day, he is very interested in something even simpler and with smaller pills. You discuss a variety of options, including bictegravir (BIC)/lenacapavir (LEN). Which of the following statements regarding the ARTISTRY-1 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen) trial is TRUE?
A. ARTISTRY-1 included people who were treatment naive without underlying HIV drug resistance
B. ARTISTRY-1 excluded those with any integrase strand transfer inhibitor (InSTI) resistance mutations
C. ARTISTRY-1 demonstrated that BIC/LEN is the best studied switch option for those who are virologically suppressed with highly nRTI-resistant virus
D. ARTISTRY-1 demonstrated that this patient would be less likely to remain suppressed if switched to a second-generation InSTI + FTC/TAF than if switched to BIC/LEN
Register for the Chicago Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE
